• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-Effectiveness of Dabigatran vs. Rivaroxaban and Vitamin K Antagonists in Elderly Patients with Nonvalvular Atrial Fibrillation in Spain
The aim of the study is to assess the relative cost-utility of dabigatran and rivaroxaban as two currently commercialised direct oral anticoagulants (DOACs) in Spain compared with vitamin K antagonists (VKA) in the prevention of stroke and systemic embolism in elderly patients ( ≥75 years) with non-valvular atrial fibrillation (NVAF).
Source: Value in Health - October 29, 2016 Category: Global & Universal Authors: N Schoenherr, S Soulard, C Crespo, G Ram írez, J Darbà Source Type: research

Analysis of The Costs Associated with Vitamin K Antagonist Treatment for Stroke Prevention in Non Valvular Atrial Fibrialltion in Mexico
The objective of this research was to quantify the collective costs of VKA treatment for patients with non-valvular atrial fibrillation (NVAF) in Mexico.
Source: Value in Health - October 29, 2016 Category: Global & Universal Authors: J Briere, K Bowrin, R Wood, T Holbrook, J Roberts Source Type: research

Analysis of The Costs Associated with Vitamin K Antagonist Treatment for Stroke Prevention in Non Valvular Atrial Fibrialltion in Russia
This study explores the economic burden of VKA therapy from a collective perspective for Russian patients with NVAF.
Source: Value in Health - October 29, 2016 Category: Global & Universal Authors: J Briere, K Bowrin, R Wood, T Holbrook, J Roberts Source Type: research

Trends in the Utilization of Warfarin and Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
Warfarin has been used for more than 60 years to decrease the risk of stroke and death in patients with atrial fibrillation (AF). In recent years, the FDA has approved four non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in AF: dabigatran, rivaroxaban, apixaban, and edoxaban.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Alalwan, S Voils, A Hartzema Source Type: research

Effectiveness And Safety Of Reduced Dose Non-Vitamin K Antagonist Oral Anticoagulants In Patients Without Severe Renal Impairment
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has been a major advance for stroke prevention in atrial fibrillation. Because NOACs have significant renal clearance, dose reduction is needed in patients with severe kidney disease. However, some physicians may prescribe reduced-dose NOACs to patients with relatively good renal function due to the concerns over the bleeding risk. We sought to investigate the use and clinical outcomes of reduced-dose NOACs in patients without severe renal impairment.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: X. Yao, N.D. Shah, L.R. Sangaralingham, B.J. Gersh Source Type: research

Patterns and Predictors of Discontinuation and Switch in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Recent clinical trials have established non-vitamin K antagonist oral anticoagulants (NOACs) as viable alternatives to warfarin in stroke prevention for atrial fibrillation. A major challenge in routine clinical practice is the high rate of medication discontinuation and switching. There are currently few large studies offering estimates of drug persistence with NOACs. Moreover, little is known about what drives patients’ choice and behavior regarding patterns of long-term medication use. Using a large heterogeneous cohort of patients, we aimed to investigate the patterns and predictors of switch and discontinuation amon...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: X Yao, ND Shah, LR Sangaralingham, BJ Gersh, PA Noseworthy Tags: CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes & Patient Preference Studies Source Type: research

The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce. ...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research

Pages: 1  2